Mobile

A double-blind randomized placebo controlled crossover study of AZD7371 ER 5 mg bid, 20 mg bid and placebo treatment for one week on visceral perception and symptoms in patients with Irritable Bowel S...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000383-27

A double-blind randomized placebo controlled crossover study of AZD7371 ER 5 mg bid, 20 mg bid and placebo treatment for one week on visceral perception and symptoms in patients with Irritable Bowel Syndrome

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to evaluate the effect of AZD7371 20 mg bid, AZD7371 5 mg bid and placebo on rectal sensitivity during rectal distension by assessment of discomfort by using a newly developed Sensitivity Index (SI).

Critère d'inclusion

  • Irritable Bowel Syndrome (IBS)

Liens